Phytopharm Share Discussion Threads

[mrsapeslaptop] 11/5/2012 11:18

agree Dr B. with the lessons after the alzheimers myogane trial (i.e. didnt go on long enough) you would have thought that they would have taken more care.

oh well.

[dr biotech] 11/5/2012 09:42

Looks like a bodged trial to me. Seen too many of those, inconclusive result, waste of money.

[ferdy1] 11/5/2012 07:22

Disappointing results....Oh well

[mrsapeslaptop] 08/5/2012 11:31

I hope they are not waiting until results at the end of the month.

It was supposed to be March for Glaucoma, then they put it back a month.

But if succesfull heres an interesting article from last week. US market size is over $2Bn. IF IF IF the news is good we could go to P2 fairly quickly.

[ferdy1] 04/5/2012 15:18

News on Tuesday?

[mrsapeslaptop] 30/4/2012 10:16

glaucoma news is due. hurry up.

[mrsapeslaptop] 20/4/2012 08:54

ALS will be a $BN pa market with an effective drug, and we have enough data now for licencing discussions. also with orphan designation, and changes to the rules in the US it could be on sale commercially after Phase 2 only.

Glaucoma nes still to come in the next 2 weeks.

[gnomet2] 18/4/2012 14:13

This is the current competition for ALS - not much of a wonder drug !



"Studies of efficacy

A Cochrane Library review states a 9% gain in the probability of surviving one year. In secondary analyses of survival at separate time points, there was a significant survival advantage with riluzole 100 mg at six, nine, 12 and 15 months, but not at three or 18 months.[5] There was a small beneficial effect on both bulbar and limb function, but not on muscle strength. There were no data on quality of life, but patients treated with riluzole remained in a more moderately affected health state significantly longer than placebo-treated patients.
[edit]
Clinical use

While riluzole has been proven to slow down ALS, patients do not report any subjective improvement. Approximately 10% of patients experience side effects such as nausea and fatigue which lead them to discontinue treatment. Safety monitoring includes regular liver function tests and people with liver disease such as hepatitis should be monitored especially carefully.

In the UK riluzole has been available through the NHS since 1997 at a standard dosage of 50 mg twice daily. There has been some evidence to show that higher doses might produce more significant improvements in ALS patients but at £5 a tablet it is at risk of being prohibitively expensive given the modest benefit to patients. One study in the Netherlands found that riluzole is metabolised differently by males and females, and its levels in plasma are decreased in patients who smoke cigarettes or take omeprazole.[6] [7]

A number of recent case studies have also indicated that riluzole may have clinical use in mood and anxiety disorders. It has been shown to have antidepressant properties in the treatment of refractory depression[8] and as an anxiolytic in obsessive-compulsive disorder[9] and in GAD.[10]"

[somerset lad] 18/4/2012 06:33

On 23.1.12, Edison envisaged that PYM would license Cogane for ALS BEFORE it moves into clinic. The data released today will obviously be important for any such negotiations.

[topinfo] 18/4/2012 06:18

Pretty damn Excellent news that. Remember OXB the other day. PYM day today on that news. No wonder 200k bought yesterday in one trade!

[topinfo] 18/4/2012 06:04

Research Update
Print
Alert

TIDMPYM

RNS Number : 5216B

Phytopharm PLC

18 April 2012

18 April 2012

Phytopharm plc

Recruitment into CONFIDENT--PD Phase II study in Patients with Parkinson's disease complete

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that recruitment into the proof of concept Phase II study in patients with Parkinson's disease (CONFIDENT--PD) is complete. The study will complete in early December this year, following a 28-week treatment and 4-week follow-up period. Headline results from the study are expected in February 2013.

The study is investigating the efficacy, safety and tolerability of Cogane(TM) administered to over 400 patients with early stage Parkinson's disease. Three doses of Cogane(TM), administered orally once daily, are being compared with placebo. The primary endpoint for the study is the change from baseline to end of treatment in activities of daily living and motor function as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) Parts II and III. Secondary endpoints include measures of non-motor symptoms, including cognitive function. The study is being conducted in leading movement disorder centres in North America and Europe.

Mr Tim Sharpington, CEO, Phytopharm, said, "Completion of recruitment into this clinical study in patients with Parkinson's disease is an important milestone for Phytopharm. We look forward to receiving the results from the study early next year."

[topinfo] 18/4/2012 06:04

DJ Phytopharm PLC Research Update

TIDMPYM

RNS Number : 5219B

Phytopharm PLC

18 April 2012

18 April 2012

Phytopharm plc

Confirmatory data supports effectiveness of Cogane(TM) in Amyotrophic Lateral Sclerosis

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that the histopathology data from its previously reported study of Cogane(TM) in a genetic preclinical model of amyotrophic lateral sclerosis (ALS), further supports the efficacy of Cogane(TM) in ALS.

The study was performed in a model that has a mutation in the SOD1 gene (SOD1(G93A) ); mutation of the SOD1 gene is a known cause of ALS in humans. In this study, Cogane(TM) was administered orally for 50 days, commencing after ALS--type symptoms were manifest. This is therefore considered to be a model of severe, late-stage ALS.

In January of this year the Company reported preliminary data from the study demonstrating that administration of Cogane(TM) resulted in a 30--50% improvement in muscle strength in one muscle type compared to both the untreated control group and a group treated with riluzole (currently the only product marketed for the treatment of ALS). Treatment with Cogane(TM) also resulted in an increase in the number of motor units (a measure of functional motor neurones) compared with both the untreated and riluzole treated groups.

The Company is now able to report that the histopathology data from this study shows that administration of Cogane(TM) reduced the loss of spinal cord motor neurones by 39% compared with the number damaged in the untreated animals (a statistically significant difference; p=0.008). Treatment with riluzole resulted in a 29% but not statistically significant reduction. Additionally, microscopic examination showed that Cogane(TM) protected muscle composition, supporting the results reported previously on muscle strength.

This study was performed by Professor Linda Greensmith's group at University College, London, with the financial support of the Motor Neurone Disease Association, a UK based charitable organisation.

Mr Tim Sharpington, CEO, Phytopharm, said, "We are pleased that these additional data support the preliminary findings from this study. Cogane(TM) has been shown to be effective in a number of pre-clinical models of ALS, underlining its potential to be a significant new treatment for this disease. We would like to thank the Motor Neurone Disease Association for their support of this study."

[mrsapeslaptop] 17/4/2012 15:13

the company confirmed timescales to me. so glaucoma news within 2 weeks.

[mrsapeslaptop] 13/4/2012 21:30

yippee . there is three of us now.

[gnomet2] 13/4/2012 15:27

Hi folk.

I've been a long term PYM lurker and just bought in with a £10k stake at 7.11 p.

[mrsapeslaptop] 04/4/2012 14:08

glaucoma news due this month (April)

a recent article by one of phytopharms doctors who is investigating it

[mrsapeslaptop] 28/3/2012 07:51

did anyone go to the AGM ?

[enigma2002] 12/3/2012 09:51

yeh... guess i was hoping for some sort of fizzle off the back of the hoodia chatter... never mind though as you say lots to look forward to this year :-)

[mrsapeslaptop] 12/3/2012 09:49

not today. but before year end. within 9 months. which is not that long. or at any point befre

[enigma2002] 12/3/2012 09:43

well.... not much happened (yet) :D

[enigma2002] 11/3/2012 21:05

there is a lot of internet chatter about this at the moment hopefully be a good day tomorrow

[enigma2002] 11/3/2012 20:58

completele agree :D:D exciting times may be ahead


enigma2002 - 16 Jan 2012 - 09:21:42 - 135 of 184

getting there slowly but surely... the talk of renewed interest in Hoodia is particularly encouraging - weight loss, afterall, is an enormous market these results on top all add up to a good thing :D.

[mrsapeslaptop] 11/3/2012 20:55

and Nestle own Jenny Craig.......
hmm. and hmmm. The CSIR have shown that hoodia does seem to work in solid formation.
Pfizer & Unilever backed out with PYM over efficacy on a liquid formulation.

PYM used to be 600p per share on the diet side.

[mrsapeslaptop] 09/3/2012 17:50

oooh- what are the odds its hoodia back on the agenda with nestle......